An official website of the United States government
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

The most recent appropriations for the Department of War expired at 11:59 p.m. EST on September 30, 2025. Military personnel will continue in a normal duty status without pay until such time as a continuing resolution or appropriations are passed by Congress and signed into law. Civilian personnel not engaged in excepted activities will be placed in a non-work, non-pay status.

If you have a scheduled appointment or other business at the MTF, please verify with your provider or applicable office within the MTF to ensure there are no changes in schedule. To learn how the lapse in appropriations affects your TRICARE benefit, visit www.tricare.mil/shutdown

News & Gallery

Articles

News | Oct. 26, 2022

BAMC offers new prostate cancer therapy for patients

By Lori Newman

JOINT BASE SAN ANTONIO, Texas  –   The Brooke Army Medical Center Department of Nuclear Medicine is now offering a newly approved treatment for patients who have prostate cancer.

Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society estimates that 268,490 men in the United States will be diagnosed with prostate cancer this year.

On March 23, 2022, the Food and Drug Administration approved the use of lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.

Full Story
Don’t forget to keep your family’s information up to date in DEERS!